Specific CD4 down-modulating compounds with potent anti-HIV activity
- PMID: 12960237
- DOI: 10.1189/jlb.0403177
Specific CD4 down-modulating compounds with potent anti-HIV activity
Abstract
Despite the availability of the current clinically approved anti-HIV drugs, new classes of effective antiviral agents are still urgently needed to combat AIDS. A promising approach for drug development and vaccine design involves targeting research on HIV-1 entry, a multistep process that comprises viral attachment, coreceptor interactions, and fusion. Determination of the viral entry process in detail has enabled the design of specific agents that can inhibit each step in the HIV entry process. Therapeutic agents that interfere with the binding of the HIV envelope glycoprotein gp120 to the CD4 receptor (e.g., PRO 542, PRO 2000, and CV-N) or the coreceptors CCR5 and CXCR4 (e.g., SCH-C and AMD3100) are briefly outlined in this review. The anti-HIV activity of cyclotriazadisulfonamides, a novel class of compounds with a unique mode of action by down-modulating the CD4 receptor in lymphocytic and monocytic cells, is especially highlighted. On the basis of the successful results of T-20, the first approved entry inhibitor, the development of effective antiretrovirals that block HIV entry will certainly be further encouraged.
Similar articles
-
Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.J Antimicrob Chemother. 2005 Aug;56(2):270-2. doi: 10.1093/jac/dki208. Epub 2005 Jun 24. J Antimicrob Chemother. 2005. PMID: 15980096 Review.
-
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.Virology. 2005 Sep 1;339(2):213-25. doi: 10.1016/j.virol.2005.06.008. Virology. 2005. PMID: 15996703
-
The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.Biochem Biophys Res Commun. 1998 Jul 30;248(3):841-5. doi: 10.1006/bbrc.1998.9060. Biochem Biophys Res Commun. 1998. PMID: 9704015
-
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.Int J Biochem Cell Biol. 2004 Sep;36(9):1800-22. doi: 10.1016/j.biocel.2004.02.015. Int J Biochem Cell Biol. 2004. PMID: 15183346 Review.
-
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).Virology. 2005 Jul 20;338(1):182-99. doi: 10.1016/j.virol.2005.04.035. Virology. 2005. PMID: 15935415
Cited by
-
HIV entry inhibitors and their potential in HIV therapy.Med Res Rev. 2009 Mar;29(2):369-93. doi: 10.1002/med.20138. Med Res Rev. 2009. PMID: 18720513 Free PMC article. Review.
-
Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies.J Med Chem. 2016 Mar 24;59(6):2633-47. doi: 10.1021/acs.jmedchem.5b01832. Epub 2016 Mar 14. J Med Chem. 2016. PMID: 26974263 Free PMC article.
-
Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.J Virol. 2009 Sep;83(18):9577-83. doi: 10.1128/JVI.00648-09. Epub 2009 Jul 1. J Virol. 2009. PMID: 19570853 Free PMC article.
-
Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds.J Med Chem. 2021 Sep 9;64(17):12865-12876. doi: 10.1021/acs.jmedchem.1c00943. Epub 2021 Aug 24. J Med Chem. 2021. PMID: 34428050 Free PMC article.
-
Fever therapy revisited.Br J Cancer. 2005 Feb 14;92(3):421-5. doi: 10.1038/sj.bjc.6602386. Br J Cancer. 2005. PMID: 15700041 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
